|
(11) | EP 0 394 872 A1 |
| (12) | EUROPEAN PATENT APPLICATION |
|
|
|
|
|||||||||||||||||||||||||||
| (54) | Interferon for the use in the prevention or treatment of swine pneumonia or related bacterial diseases |
| (57) Methods of preventing or treating swine pneumonia or similar diseases are disclosed
using porcine interferon alpha and/or gamma, preferably recombinant porcine interferon
alpha and/or gamma. |
[0001] This invention relates to the use of interferon (IFN) alpha and gamma for the treatment and preferably for the prevention of swine pneumonia caused by Haemophilus (Actinobacillus) pleuropneumoniae, or related bacterial diseases.
[0002] IFN alpha and gamma are produced by immune cells in the body and regulate immune functions such as antibody production, expression of cell-surface antigens and T cell maturation and differentiation. IFN gamma is also the best known and characterized macrophage activating factor. In recent years, IFN gamma has been shown to exert a suppressive effect on infections caused by a wide range of nonviral pathogens including rickettsiae, chlamydiae, fungi, bacteria and protozoa. Furthermore, in concert with other cytokines, IFN gamma has been shown to be involved in the regulation of acute inflammatory responses to bacterial lipopolysaccharides.
[0003] The bacterium Actinobacillus (Haemophilus) pleuropneumoniae is the cause of an often fatal respiratory disease in swine known as porcine Haemophilus pneumonia (PHP). The acute form of the disease is manifested by the sudden onset of clinical manifestations and high mortality. Early symptoms of the acute form of the disease include elevated temperature, respiratory distress, cyanosis, vomiting, lethargy and depression. However, sudden death is often the only clinical manifestation in some animals. PHP is not always fatal; some swine become infected and remain asymptomatic carriers. Significant economic losses also arise from the development of chronic lesions with subsequent reduction of productive performance in the survivors.
[0004] The pathogenesis of PHP has not been completely elucidated. Nevertheless, the pathology caused by A. pleuropneumoniae in the peracute and acute forms of the disease has been compared to that of endotoxic shock. The lesions consist of alveolar and interlobular edema, congestion, endothelial damage and hemorrhage, and intravascular fibrinous thrombosis. The end result is commonly acute circulatory collapse. It has been shown that intravenous (IV) injection of sterile PHP pneumonia lung suspension in pigs induces bilateral renal cortical necrosis, similar to that seen in a generalized Schwartzman reaction. The Schwartzman reaction can be induced with most gram-negative bacteria and, in some instances, this reaction becomes an important component of the disease pathogenesis.
[0005] Studies on the regulation of LPS-induced Schwartzman reaction have shown that antibodies against IFN gamma as well as parenteral administration of all IFN types suppress the local Schwartzman reaction. These results have been used to postulate that, within the inflammatory focus, IFN gamma acts as a pro-inflammatory cytokine, while in the circulation they exhibit anti-inflammatory properties. These anti-inflammatory properties of systemic IFN's have been suggested to be mediated indirectly through centrally regulated endocrine or neuroendocrine mechanisms. IFN alpha has also been suggested to play a role in the regulation of acute inflammatory responses.
[0006] The use of anti-IFN gamma has been proposed to aid in the control of clinical manifestations resembling a Schwartzman reaction such as acute inflammatory reactions associated with acute vascular thrombosis and certain chronic disorders associated with uncontrolled macrophage activation. All attempts to prevent and control PHP have met with limited success.
[0008] Haemophilus pleuropneumoniae of Pigs, VIDO Views, Fact Sheet No. 10, April 1985.
Sebunya, T.N.K. and Saunders, J.R. (1983) Haemophilus pleuropneumoniae Infection in Swine: A Review. J.A.V.M.A. 182:1331-1337.
Billiau, A. (1980) Gamma Interferon: The Match that Lights the Fire. Immunol. Today 9:37-40.
Heremans, H. et al. (1987) Regulation by Interferons of the Local Inflammatory Response to Bacterial Lipopolysaccharide. J.Immunol. 130:4175-4179.
Kiderlen, A.F. et al. (1984) Protection of Mice Against Intracellular Bacterium Listeria Monocytogenes by Recombinant Immune Interferon. Eur. J. Immunol. 14:964-967.
Buchmeier, N. et al. (1985) Requirement of Endogenous Interferon - Production for Resolution of Listeria Monocytogenes Infection. Proc. Natl. Acad. Sci. USA 82:7404-7408.
Bhardwaj, N. et al. (1986) Gamma Interferon-Activated Human Monocytes Inhibit the Intracellular Multiplication of Legionella Pneumophilia. J. Immunol. 137:2662-2669.
Edwards III, C.K. et al. (1986) Chronic Infection Due to Mycobacterium Intracellulare in Mice. Association with Macrophage Release of Prostaglandin E2 and Reversal by Injection of Indomethacin, Muramyl Dipeptide or Interferon. J. Immunol. 136:1820-1827.
Charley, B. et al. (1988) Antiviral and Antigenic Properties of Recombinant Porcine Interferon Gamma. Vet. Immunol. & Immunopath. 19:95-103.
[0009] It has been surprisingly discovered that porcine natural and preferably recombinant interferon alpha and gamma (PoIFN-alpha and -gamma) protect pigs against acute PHP. The results reported here are particularly surprising in view of the previous failures of the art to develop an effective control for PHP. Furthermore, it is believed that the present invention provides an effective method of preventing and treating other swine diseases having a similar pathogenesis to PHP.
[0010] In one embodiment, the present invention is directed to a method for the treatment and preferably for the prevention of swine pneumonia or related bacterial swine diseases which method comprises administering to a swine an interferon selected from the group consisting of porcine interferon alpha and porcine interferon gamma, preferably recombinant porcine IFN-alpha and recombinant porcine IFN-gamma wherein said interferon is administered to a sick or preferably to a healthy swine or to a group of swines among which individual animals show first symptoms in a dose rate of about 10 µg to about 1000 µg per animal or of 0.1 µg/kg bodyweight to about 100 µg/kg bodyweight.
[0011] Another embodiment of the present invention is directed to a method of treating or preventing pneumonia in swine comprising administering to said swine a dosage of interferon or recombinant interferon effective in treating or preventing pneumonia, wherein said interferon is selected from the group consisting of porcine interferon alpha and porcine interferon gamma, preferably recombinant PoIFN-alpha and recombinant PoIFN-gamma, especially recombinant PoIFN-gamma.
[0012] In a further preferred embodiment said dose rate of porcine interferon is administered to a healthy pig or to a group of pigs among which individual animals show first symptoms.
[0013] In yet another embodiment, the present invention is directed to a method of treating or preventing a disease in swine, wherein said disease is caused by infection by a bacterium selected from the group consisting of Actinobacillus pleuropneumoniae, Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus and Actinobacillus suis, said method comprising administering a dosage of interferon to said swine that is effective in treating or preventing said disease, when said interferon is selected from the group consisting of porcine interferon alpha and porcine interferon gamma.
[0014] Another preferred embodiment of the present invention is directed to a method for controlling bacteria selected from the group consisting of Actinobacillus pleuropneumoniae, Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus and Actinobacillus suis, said method comprising administering a bactericidally effective amount of a natural or preferably a recombinant procine interferon alpha or a natural or preferably a recombinant porcine interferon gamma to said bacteria or to the locus thereof.
[0015] A further preferred embodiment of the present invention is directed to porcine interferon alpha or porcine interferon gamma preferably recombinant porcine interferon alpha or recombinant interferon gamma for the treatment or preferably the prevention of swine pneumonia or related bacterial swine diseases.
[0016] Another preferred embodiment of the present invention is directed to the use of porcine interferon alpha or porcine interferon gamma preferably of recombinant porcine interferon alpha or recombinant porcine interferon gamma for the preparation of a pharmaceutical preparation for the treatment or preferably the prevention of swine pneumonia or related bacterial swine diseases.
[0017] Additional and preferred embodiments of the present invention will be readily apparent to those of ordinary skill from the following disclosure.
Brief Description of the Figures
[0018]
FIG. 1 shows the nucleotide and amino acid sequences for a gene suitable for the recombinant production of PoIFN-alpha.
FIG. 2 shows the nucleotide and amino acid sequences for a gene suitable for the recombinant production of PoIFN-gamma.
[0019] Thus, the present invention is directed to the treatment or preferably the prevention of disease, such as pneumonia, in swine, by the administration of porcine interferon (PoIFN) alpha and/or gamma. A preferred embodiment of the invention is the treatment or prevention of PHP. Furthermore, the present invention is directed to the use of these interferons to prevent disease (such as other pneumonias) with pathogenic mechanisms similar to those of Actinobacillus pleuropneumoniae, such as diseases caused by, but not limited to, Pasteurella hemolytica, Pasteurella multocida, Haemophilus somnus, and Actinobacillus suis. It is also preferred to practice the present invention with juvenile swine (piglets), particularly to prevent disease.
[0020] The present invention contemplates employing any form of PoIFN-alpha or -gamma, either alone or in combination. Thus, the present invention encompasses using native forms of the interferons. Particularly surprising, however, is that recombinant forms of the interferons have sufficient biological activity to be effective treatments for the diseases discussed above. Since the production of recombinant interferon has substantial advantages relative to the purification of native polypeptides, recombinant interferons are a preferred embodiment. It is also contemplated that synthetic forms of PoIFN, and muteins or fragments of PoIFN exhibiting effective biological activity, are also within the scope of the invention. A mutein of a PoIFN is a polypeptide substantially homologous to the native protein, and more homologous to the porcine form than to IFN's from other species. A fragment of PoIFN is a polypeptide that is homologous to a region of sufficient length in the protein such that the sequence is unique to PoIFN.
[0021] The production of recombinant animal interferons, including alpha (leukocyte) and gamma (immune), is known in the art. See, e.g., EPO Pub. No. 088,622 by D. Capon & D. Goeddel. FIGs. 1 and 2 show nucleic acid sequences (and the corresponding amino acid sequences) of genes for the production of rPoIFN-alpha and gamma, respectively. The cloning of rPoIFN-alpha has been reported. Lefevre & La Bonnardiere (1986) J. Interferon Res. 6:349-360. The antiviral and antigenic properties of rPoIFN-gamma have also been studied. Charley et al. (1988) Vet. Immunol. & Immunopath. 19:95-103. Thus, the production of rPoIFN-alpha and gamma is within the skill of the art.
[0022] As indicated, the present invention is concerned with treating or preventing disease. By "treating" is meant curing or ameliorating an animal that has contracted the disease in question. "Preventing" a disease means preventing the occurrence of the disease in question, or tempering the severity of the disease if it is later contracted.
[0023] The dosages of the interferons which can treat or prevent a disease can be determined in view of this disclosure by one of ordinary skill in the art by running routine trials with appropriate controls. Comparison of the appropriate treatment groups to the controls will indicate whether a particular dosage is effective in preventing or treating a disease used in a controlled challenge. In general, effective dosages will depend on the weight of the animal and will typically run in the range of from about 0.1 µg/kg bodyweight to about 40 µg/kg bodyweight. More typically, the dosage will be at least about 1 µg/kg bodyweight, or equal to or less than 10 µg/kg bodyweight. On an absolute basis per animal, single-dose formulations will contain from about 10 µg to about 1000 µg. More typically, preferred single-dose formulations per animal will be at least about 30 µg, 100 µg or even 200 µg, but usually no more than about 600 µg or 700 µg. Effective dosages are believed to fall within a relatively wide range.
[0024] Beyond dosage, an effective administration of interferons according to the present invention will in part depend on the number and timing of the dosages. For example, multiple administrations of a dosage may be given to an animal, typically at least about 24 hours apart. In some circumstances it may be desirable to administer the interferon at least twice to the animal, or at least three times. It may even be desirable to administer even more dosages to the animal, such as six, seven, eight, or even nine over an equal number of days or longer. Again, it is believed that the precise combination of dosage and timing will be subject to a wide range of variation and that numerous combinations effective in treating or preventing a disease can be readily established by those of ordinary skill in the art in view of the present disclosure.
[0025] Typically, the present invention contemplates parenteral administration of the interferon to the animal. Particularly convenient is intramuscular (IM) injection. However, effective dosages may be administered by intravenous (IV) injection, although such a route is not typically preferred in the field. Thus, the IFN will usually be placed in a suitable parenteral vehicle. It may also be formulated into effective oral dosages, pulmonary aerosols or suppositories.
[0026] Described below are several examples illustrating the practice of the present invention. These examples are provided for illustrative purposes only, and are not intended to limit the scope of the appended clalms.
EXAMPLES
Materials and Methods
[0027] a. Recombinant porcine interferons: Recombinant PoIFN-gamma (Lot No. 4646/58) and rPoIFN-alpha (Lot No. 5062-38B) were supplied by CIBA-GEIGY CANADA Ltd. (Mississauga, Ontario). The preparation of rPoIFN-gamma (1.6 mg/ml) had a specific antiviral activity of 4.8 X 10⁷ U/mg, and the preparation of rPoIFN-alpha (1.5 mg/ml) had a specific antiviral activity of 1 X 10⁸ U/mg. The specific antiviral activity of both preparations was quantitated with a bioassay based on a plaque reduction assay using vesicular stomatitis virus (VSV) on porcine kidney cells.
[0028] b. Interferon administration: Stock IFN was diluted to the desired concentration with phosphate buffer saline (PBS) and administered intramuscularly at a total volume of 2 ml/pig. Pigs in the control groups were injected with 2 ml of PBS. The dose of IFN used in each experiment as well as the times of administration are described in the results section.
[0029] c. Experimental animals: Eleven-week-old male and female pigs weighing an average of approximately 30-35 kg were purchased from various sources. At their arrival, pigs were weighed, bled for pre-challenge antibody titers, and tagged. Pigs were housed in isolation rooms at a rate of 3-4 pigs per pen and a maximum of 24 pigs per room. The isolation rooms were maintained under controlled ventilation and temperature conditions. The animals were fed commercial nonmedicated pig starter feed, following the recommended nutrition standards. Pigs were allowed 6-7 days to acclimate before the beginning of an experiment. Normal rectal temperatures and clinical scores were recorded 3-4 days prior to the challenge. Only healthy pigs with antibody titers of less than 1:100 were used in the trials. Titers of 1: 10,000 and higher are considered to be protective.
[0030] d. Groups and treatments: Pigs on the two rPoIFN-gamma trials (Examples 1 and 2) were randomized according to pens and, whenever possible, rooms, whereas on the rPoIFN-alpha trials, randomization was based on weights, pens, and, whenever possible, rooms. All inoculations were made to a volume of 2 mls and administered intramuscularly (IM).
[0031] e. Challenge: Animals were challenged at 12 weeks of age with broth culture Actinobacillus pleuropneumoniae in log phase and diluted to a concentration of 5 x 10⁴ to 1 x 10³ CFU/ml. For Example 3, the concentration of bacteria used was somewhat higher than expected, which could account for the higher mortality rate.
[0032] The bacterial solution was aerosolized via a nebulizer into a plexiglas chamber, where the pigs were placed and allowed to breathe the aerosol for 10 minutes. Five to 6 pigs from different groups (whenever possible) were challenged together.
[0033] The precise bacterial counts used for the challenge in each one of the trials was as follows:
rPoIFN-gamma Example 1: 5 x 10⁴ CFU/ml
rPoIFN-gamma Example 2: 1.2 x 10⁵ CFU/ml
rPoIFN-alpha Example 3: 2.8 x 10⁵ CFU/ml
[0034] f. Clinical evaluation: Rectal temperatures were recorded and animals were scored clinically once a day on days 1,2 and 3 post challenge. Clinical scores were based both on the severity of respiratory distress as well as on the degree of systemic involvement. The scoring categories were described as follows:
0 - normal respiration and behavior
1 - increased respiratory rate, but alert and active
2 - markedly increased and labored respiration, depressed and inactive
3 - moribund, in shock or severely dyspneic (warrants euthanasia)
4 - dead
[0035] Clinical evaluations were performed independently by two experienced individuals and averaged to produce a daily clinical score for each animal. On Experiment 6, mortality was recorded twice daily and clinical scores of pigs that died in the afternoon were a result of the average of morning and afternoon scores.
[0036] g. Post-mortem evaluation: (i). Bacteriology. Partial necropsies were performed on all animals (thoracic cavity and lung examination) and lung samples of the affected areas were taken for bacterial culture to confirm the presence of pulmonary pathology caused by Actinobacillus pleuropneumoniae.
(ii). Lung scoring. All surviving animals were euthanized at 7 to 14 days post challenge using a captive bolt gun and exsanguination. Lungs were carefully removed from the thoracic cavity to avoid disrupting the tissue. The affected areas in both the dorsal and ventral surfaces of the lung were proportionally drawn in lung maps. In the case of the two IFN gamma experiments, the percentage of pulmonary area affected was estimated, whereas for the rest of the trials, the percentage of affected pulmonary area was determined using a computerized digitizer.
[0037] Example 1 Eleven-week-old pigs weighing an average of approximately 30 kg were used. Pigs were randomly distributed into 7 groups of 6 pigs each and housed in isolation rooms.
[0038] All rPoIFN-gamma treatments shown in Table 1 were made up to a volume of 2 ml per pig and administered intramuscularly at the indicated times.
Table 1
| Experimental Protocol - Trial 1 | ||
| Group | Dose of rPoIFN Gamma (µg/pig) | Number and Timing of rPoIFN-Gamma Treatment(s)a |
| 1 | 0 | -- |
| 2 | 300 (high) | 3 inoculations at-48 hrs, -24 hrs and 0 hrs |
| 3 | 30 (interim) | 3 inoculations at-48 hrs, -24 hrs and 0 hrs |
| 4 | 3 (low) | 3 inoculations at-48 hrs, -24 hrs and 0 hrs |
| 5 | 300 (high) | single inoculation at-24 hrs |
| 6 | 30 (interim) | single inoculation at-24 hrs |
| 7 | 3 (low) | single inoculation at-24 hrs |
| aPigs were challenged with an aerosol of A. pleuropneumoniae at 0 hrs. |
[0039] Animals were challenged with a log phase culture of A. pleuropneumoniae diluted to 5 x 10⁴ bacterium/ml. This solution was aerosolized into a challenge chamber and pigs were allowed to inhale the aerosolized bacterial suspension for 10 min.
[0040] The pigs were examined for clinical signs at regular intervals following challenge. The results are listed in Table 2 below. As is shown in Table 2 ≈ 65% of the control pigs died following aerosol challenge with A. pleuropneumoniae. In contrast to the control pigs, the pigs treated with rPoIFN-gamma were protected or partially protected depending on the dose and timing of administration of the lymphokine. The most significant differences from the control group were seen in the two groups given either 1 dose of 30 µg or 1 dose of 300 µg of rPoIFN-gamma 24 hrs before challenge, and in the group given 3 doses of 300 µg. No pigs died in either of these three groups. Thus, the average level of clinical illness, as measured by a clinical score, was reduced in groups given the lymphokine as compared to the controls.
Table 2
| rPoIFN-gamma Trial 1 (Results) | |||||||
| Daily percentage mortality [M(%)] and the clinical score after challenge with Actinobacillus pleuropneumoniae means by groups | |||||||
| Tx | Group # | Day 1 | Day 2 | Day ≧ 3 | |||
| M (%) | C. Score | M (%) | C. Score | M (%) | C. Score | ||
| Control | 1 | 33.3 | 2.00 | 66.7 | 2.75 | 66.7 | 2.75 |
| 300 µg/pig -48, -24, 0 hrs | 2 | 0 | 0.92 | 0 | 0.92 | 0 | 0.75 |
| 30 µg/pig -48, -24, 0 hrs | 3 | 0 | 0.92 | 16.7 | 1.75 | 33.3 | 1.92 |
| 3 µg/pig -48, -24, 0 hrs | 4 | 16.7 | 1.50 | 33.3 | 2.17 | 50.0 | 1.92 |
| 300 µg/pig -24 hrs | 5 | 0 | 1.25 | 0 | 1.25 | 0 | 0.83 |
| 30 µg/pig -24 hrs | 6 | 0 | 1.00 | 0 | 1.25 | 0 | 0.67 |
| 3 µg/pig -24 hrs | 7 | 16.7 | 1.50 | 50.0 | 2.00 | 50.0 | 2.00 |
| 6 pigs/group | |||||||
[0041] Example 2: The experiment consisted of 3 groups of 8 pigs each. The groups were treated with rPoIFN-gamma at the doses and times shown in Table 2. Challenge was similar to Example 1 except for the dose of A. pleuropneumoniae which was used at a dilution of 1.2 x 10⁵.
Table 3
| Experimental Protocol - Trial 2 | ||
| Group | Dose (µg/pig) | Number and Timing of rPoIFN-Gamma Treatments |
| 2 | 0 | -- |
| 3 | 600 | Single dose at-24 hrs |
| 1 | 300 | Triple dose at-48 hrs, -24 hrs and 0 hrs |
[0042] The outcome is summarized in Table 4 below. In this trial, up to 37.5% of the untreated control pigs died. In contrast, the mortality rate was 25% in the pigs given a single dose of 600 µg of rPoIFN and 0% in the group given 3 doses of 300 µg. A similar reduction in the severity of the clinical scores was also observed.
Table 4
| rPoIFN-gamma Trial 2 (Results) | |||||||
| Daily percentage mortality [M(%)] and the clinical score after challenge with Actinobacillus pleuropneumoniae | |||||||
| Means by groups | |||||||
| Tx | Group # | Day 1 | Day 2 | Day ≧ 3 | |||
| M (%) | C. Score | M (%) | C. Score | M (%) | C. Score | ||
| 300 µg/pig -48, -24, 0 hrs | 1 | 0 | 0.87 | 0 | 0.75 | 0 | 0.69 |
| Control | 2 | 12.5 | 1.09 | 25.0 | 2.00 | 37.5 | 2.00 |
| 600 µg/pig -24 hrs | 3 | 0 | 1.34 | 12.5 | 1.56 | 25.0 | 1.41 |
| 8 pigs/group | |||||||
[0043] Example 3: The experimental protocol used for this example was the same as that of Example 1, substituting rPoIFN-gamma with rPoIFN-alpha. Bacterial challenge in the experiment was more severe (100% mortality in the untreated control group) than in previous experiments when rPoIFN-gamma was used. Nevertheless, except for one group (triple intermediate dose), pigs treated with rPoIFN-alpha were protected or partially protected from acute PHP. Pigs treated with either a single high or a single intermediate dose showed the least clinical scores and the lowest mortality. The results are summarized in Table 5 below.
[0044] This additional example confirms that the administration of cytokines involved in the regulation of acute inflammatory reactions will prevent the acute form of PHP. Thus, the use of rPoIFN-alpha alone and in combination with rPoIFN-gamma and/or other cytokines involved in the regulation of acute inflammation for control and treatment of PHP and similar diseases is shown.
Table 5
| rPoIFN-gamma Trial 2 (Results) | |||||||
| Daily percentage mortality [M(%)] and the clinical score after challenge with Actinobacillus pleuropneumoniae | |||||||
| Means by groups | |||||||
| Tx | Group # | Day 1 | Day 2 | Day 3 | Day 3 | ||
| M (%) | C. Score | M (%) | C. Score | M (%) | C. Score | ||
| 300 µg/pig -24hrs | 1 | 0 | 1.25 | 28.6 | 2.11 | 28.6 | 1.96 |
| 3 µg/pig -48, -24, 0 hrs | 2 | 42.9 | 2.14 | 57.1 | 2.57 | 57.1 | 2.61 |
| 300 µg/pig -24hrs | 3 | 0 | 1.07 | 14.3 | 1.61 | 28.6 | 1.68 |
| Control | 4 | 42.9 | 2.43 | 85.7 | 3.71 | 100.0 | 4.00 |
| 300 µg/pig -48, -24, 0 hrs | 5 | 28.6 | 1.96 | 71.4 | 3.14 | 71.4 | 2.96 |
| 3 µg/pig -24hrs | 6 | 14.3 | 1.79 | 85.7 | 3.43 | 85.7 | 3.43 |
| 30 µg/pig -48, -24, 0 hrs | 7 | 50.0 | 2.67 | 83.3 | 3.67 | 100.0 | 4.00 |
| Groups 1, 2, 3, 4, 5 and 6 = seven pigs each | |||||||
| Group 7 = six pigs | |||||||
[0045] Example 4: This example compares the efficacy of rPoIFN-alpha with that of recombinant bovine alpha interferon (rBoIFN-alpha) against A. pleuropneumoniae disease.
[0046] Forty-eight pigs (11 weeks old) were randomized into 3 groups based on weight and litter origin. Two groups were treated with either rPoIFN-alpha or rBoIFN-alpha (100 µg/pig), respectively, 24 hrs prior to bacterial challenge. Subsequent procedures were the usual except that blood was collected prior to and 24 hours after challenge from 5 pigs from each group. Tissues were collected for histopathology from dead or euthanized pigs. As in Example 3, rPoIFN-alpha once again proved efficient in reducing clinical pleuropneumonia and death. The rBoIFN-alpha group did not differ significantly from the control group, whereas the rPoIFN-alpha treated group did. The results are summarized in Table 6. Histopathologically the groups could not be separated out, leading to the conclusion that although IFN may ameliorate clinical performance and prevent death, it does not abolish development of chronic pathological lesions.
Table 6
| Comparison between rPoIFN-gamma and rPoIFN-alpha | |||||||
| Daily percentage mortality [M(%)] and the clinical score after challenge with Actinobacillus pleuropneumoniae | |||||||
| Means by groups | |||||||
| Tx | Group # | Day 1 | Day 2 | Day ≧ 3 | |||
| M (%) | C. Score | M (%) | C. Score | M (%) | C. Score | ||
| Control | 1 | 37.5 | 2.06 | 75.0 | 3.16 | 81.2 | 3.30 |
| rBoIFNα 100 µg/pig | 2 | 25.0 | 1.70 | 62.5 | 2.92 | 62.5 | 2.73 |
| rBoIFNγ 100 µg/pig | 3 | 12.5 | 1.09 | 37.5 | 1.83 | 37.5 | 1.81 |
| 16 pigs/group | |||||||
Table 7
| rPoIFN-alpha Trial 3 (Results) | |||||||
| Daily percentage mortality [M(%)] and the clinical score after challenge with Actinobacillus pleuropneumoniae | |||||||
| Means by groups | |||||||
| Tx | Group # | Day 1 | Day 2 | Day ≧ 3 | |||
| M (%) | C. Score | M (%) | C. Score | M (%) | C. Score | ||
| 10 µg/kg -24 hrs | 1 | 0 | 0.50 | 16.7 | 0.96 | 25.0 | 0.96 |
| Control | 2 | 33.3 | 1.75 | 58.3 | 2.46 | 66.7 | 2.46 |
| 40 µg/kg -24 hrs | 3 | 0 | 0.58 | 8.3 | 0.67 | 16.7 | 0.50 |
| 24 µg/kg -24 hrs | 4 | 0 | 0.46 | 25.0 | 1.29 | 33.3 | 1.54 |
| 12 pigs/group | |||||||
| Note: mortality recorded up to day 5. | |||||||
1. Porcine interferon alpha or porcine interferon gamma or preferably recombinant
porcine interferon alpha or recombinant interferon gamma for the treatment or preferably
the prevention of swine pneumonia or related bacterial diseases.
2. Interferon according to claim 1 for the administration to a sick or preferably
to a healthy swine in a dose rate per animal of from about 10 µg to about 100 µg or
in a dose rate of from 0.1 µg/kg bodyweight to about 100 µg/kg bodyweight.
3. Interferon according to claim 2 for the administration to a healthy pig or to a
group of pigs among which individual pigs show the first symptoms.
4. Interferon according to claim 2 wherein said dose rate is administered at least
once per day for 2 or more consecutive days.
5. Interferon according to claim 1, wherein said related bacterial disease is caused
by infection by a bacterium selected from the group consisting of Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus and Actinobacillus suis.
6. Interferon according to claim 1, wherein the swine disease is caused by Actinobacillus pleuropneumoniae and said disease is PHP.
7. Interferon according to any one of claims 1 to 6, wherein said swine is juvenile.
8. The use of porcine interferon alpha or porcine interferon gamma preferably of recombinant
porcine interferon alpha or recombinant porcine interferon gamma for the preparation
of a pharmaceutical preparation for the treatment or preferably the prevention of
swine pneumonia or related bacterial swine diseases.
9. A method for controlling bacteria selected from the group consisting of Actinobacillus pleuropneumoniae, Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus and Actinobacillus suis, said method comprising administering a bactericidally effective amount of natural
or preferably a recombinant porcine interferon alpha or natural or preferably a recombinant
porcine interferon gamma to said bacteria or to the locus thereof.
Claims for the following Contracting State(s): ES, GR
1. The use of porcine interferon alpha or porcine interferon gamma preferably of recombinant
porcine interferon alpha or recombinant porcine interferon gamma for the preparation
of a pharmaceutical preparation for the treatment or preferably the prevention of
swine pneumonia or related bacterial swine diseases.
2. The use according to claim 1 for the administration to a sick or preferably to
a healthy swine in a dose rate per animal of from about 10 µg to about 100 µg or in
a dose rate of from 0.1 µg/kg bodyweight to about 100 µg/kg bodyweight.
3. The use according to claim 2 for the administration to a healthy pig or to a group
of pigs among which individual pigs show the first symptoms.
4. The use according to claim 2 wherein said dose rate is administered at least once
per day for 2 or more consecutive days.
5. The use according to claim 1, wherein said related bacterial disease is caused
by infection by a bacterium selected from the group consisting of Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus and Actinobacillus suis.
6. The use according to claim 1, wherein the swine disease is caused by Actinobacillus pleuropneumoniae and said disease is PHP.
7. The use according to any one of claims 1 to 6, wherein said swine is juvenile.
8. A method for controlling bacteria selected from the group consisting of Actinobacillus pleuropneumoniae, Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus and Actinobacillus suis, said method comprising administering a bactericidally effective amount of natural
or preferably a recombinant porcine interferon alpha or natural or preferably a recombinant
porcine interferon gamma to said bacteria or to the locus thereof.